Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Decentralized Clinical Trials Are Delivering Time And Cost Efficiencies

Executive Summary

A modeling study, an analysis of a dozen clinical trials and a survey of 400 clinical trial executives all show how using decentralized elements in trials can result in faster, less expensive and more engaging research.

You may also be interested in...



Decentralized Trial Technologies An ‘Encumbrance’ For Site Personnel, US Survey Shows

The Association of Clinical Research Professionals says the perspective of personnel working at clinical research sites must be taken into account to ensure the effective implementation of decentralized clinical trials. 

COVID-19 Outlook: Variants, Boosters, And Being ‘Worse Off’ For Next Pathogens

US FDA’s Peter Marks, Pfizer’s Mikael Dolsten and other experts discuss what is being done to prepare for the future, worries about higher fatality rates, and what 2023 might look like.

Early Days For The Metaverse In The Life Sciences, But Experimentation Is Happening

Hype around the metaverse has made it a sexy topic, but a recent Accenture report grounds the concept in a sober, yet still exciting, reality. The consulting firm looked at how the metaverse is being applied in the life sciences sector and concluded that while it is early days and the concept remains nebulous, executives would be remiss if they ignored the growing possibilities the metaverse has to offer.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS147007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel